
CLIENT PROJECTS: ODTX
ODTx
OnDemand Therapeutics (ODTx), Inc. was an early stage, venture-backed medical device company. ODTx invented and patented a new way to deliver intraocular drug therapies to treat retinal conditions.
The ODTx drug delivery concept. Laser light is directed to a surgically implanted drug delivery device in the posterior chamber of the eye, activating the release of a selected pharmaceutical agent in an "on-demand" fashion.
ODTx drug delivery technology employed a surgically-implantable device containing one or more drug-agent containing micro-reservoirs. At the time of a physician's choosing, a standard ophthalmic photocoagulator laser instrument can be used to direct laser light at a desired micro-reservoir. The laser activation process enables the release of controlled amounts of drug into the posterior chamber of the eye, enabling the physician to control the timing and nature of intraocular therapy. The ODTx approach was developed to treat ocular diseases such as macular degeneration, diabetic retinopathy or uveitis. You can learn more about ODTx technology here.
Prototype ODTx device in vitro after laser activation. Green and red areas show elution of fluorescently-marked drug analogues in solution.
Gain Consulting led the initial proof of concept project for ODTx. We developed the laser-material interaction, qualified the fluorophotometry technique for pharmacokinetic and pharmacodynamic measurements, and performed the laser procedures in the initial animal studies of a prototype laser-activated drug delivery device. In collaboration with other ODTx personnel, we also co-developed new IP ('426, '804) covering laser activation of drug release.
Gain Consulting also assisted in the development and presentation of materials leading to successful Series A funding rounds from InterWest Partners.
Prototype device eluting fluorescently-labeled drugs in a live rabbit model.